Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

NCT06356584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Immunotherapy
Radiotherapy
Targeted Therapy
Liver Metastasis

Interventions

DRUG: Immunotherapy (Sintilimab)
DRUG: Targeted Therapy Agent (Fruquintinib)
RADIATION: Radiotherapy (SBRT and LDRT)

Sponsor

Shandong Cancer Hospital and Institute